Clinical Development of a Therapeutic Agent for COPD

Information

  • Research Project
  • 8495831
  • ApplicationId
    8495831
  • Core Project Number
    R44HL073591
  • Full Project Number
    2R44HL073591-07
  • Serial Number
    073591
  • FOA Number
    RFA-HL-13-016
  • Sub Project Id
  • Project Start Date
    9/29/2003 - 22 years ago
  • Project End Date
    5/31/2016 - 9 years ago
  • Program Officer Name
    CROXTON, THOMAS
  • Budget Start Date
    8/1/2013 - 12 years ago
  • Budget End Date
    5/31/2014 - 11 years ago
  • Fiscal Year
    2013
  • Support Year
    07
  • Suffix
  • Award Notice Date
    7/29/2013 - 12 years ago

Clinical Development of a Therapeutic Agent for COPD

DESCRIPTION (provided by applicant): Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, allergic rhinitis, and bronchiectasis. Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very few potential therapeutic targets. We discovered that a specific protein called MARCKS is a key molecule in the mucus secretary pathway. Based on this finding BioMarck developed a novel peptide, BIO-11006, which inhibited mucus hypersecretion as well as release of inflammatory mediators in human airway epithelial cells in culture and in various rodent models. BIO-11006, being a dual function inhibitor mucus secretion and inflammation, is an ideal drug to potentially treat various lung diseases including COPD. With funding from SBIR grants, BioMarck continued work on this project and has recently successfully completed, under an active IND, a 21-day proof-of-concept Phase 2A clinical study in 172 COPD patients suffering from chronic bronchitis with its lead compound BIO-11006. This SBIR Phase II Bridge grant application will allow BioMarck to undertake a 90-day Phase 2B multi center, double blind, dose selection clinical study with BIO-11006 with 300 COPD patients suffering from chronic bronchitis. A successful completion of the proposed project will allow BioMarck to select a dose level for the final Phase 3 clinical study. Worldwide the social and economic burden of COPD is enormous. COPD, being the 3th. leading cause of death, accounts for over 5 million deaths worldwide. Although there are more than 25 different drugs currently available in the market, the patients and the care providers are desperate for effective drugs for the treatment of COPD. BIO- 11006, by reducing both excess mucus and airway inflammation, has the potential to be a first in class drug to effectively treat this patien population.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    1000000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:1000000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZHL1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOMARCK PHARMACEUTICALS, LTD
  • Organization Department
  • Organization DUNS
    153401174
  • Organization City
    DURHAM
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    277132220
  • Organization District
    UNITED STATES